top of page

HyVir


Next-Generation Ensitrelvir: A Computational Strategy for Improving SARS-CoV-2 Main Protease Inhibition
The moderate clinical efficacy of ensitrelvir (EST) in certain treatment settings, together with the emergence of resistance-associated SARS-CoV-2 main protease (3CLpro) mutations, underscores the clinical relevance of developing next-generation EST. Structural optimization through modifications of the indazole, trifluorobenzene, and triazole groups, as exemplified by EST-YS9, may improve molecular interactions with 3CLpro and potentially enhance its physicochemical propertie
Yogy Simanjuntak
1 day ago4 min read


Beyond Ensitrelvir: Computational Identification of Novel Inhibitors of SARS-CoV-2 Main Protease with Enhanced Binding Affinity
Ensitrelvir (EST) is one of approved antiviral drugs that target SARS-CoV-2 3CLpro. EST was reported to reduce the relative risk of COVID-19 by 67% following high-risk household exposure. Intriguingly, further optimization of EST's binding properties to 3CLpro could potentially enhance its therapeutic efficacy. In my upcoming hypothesis, I employ a computational structure–binding relationship approach to design next-generation of EST with improved binding properties and thera
Yogy Simanjuntak
Nov 151 min read
bottom of page